...Merck...announced it would sell Crixivan...in some poor countries for $600 per patient per year...Merck claims that it will not make a profit...Bristol-Myers Squibb Company announced that it was making its drugs ddI and d4T available "in every country in Africa" at...[prices that] it said [are] below its cost...While we do not contest the companies' statements that they will not profit...we do note that any such calculation is based on many accounting choices, which are not public. [also refers to Cipla, Hetero Drugs]